Recent Pfizer Press Releases

  • 7/25/07 7:04 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that a Spanish court has upheld the company's enantiomer patent covering the calcium salt of atorvastatin, the active ingredient in Lipitor. The Commercial Court of First Instance Number 4 in Barcelona, which issued the ruling, found a second patent covering a stabilized formulation that includes atorvastatin is invalid. The patents were challenged by generic manufacturer Ranbaxy.more...
  • 7/25/07 12:01 am EDT
    NEW YORK--(BUSINESS WIRE)--Rates of virologic suppression in patients receiving Pfizer’s novel CCR5 antagonist, maraviroc, compared to efavirenz (EFV) were 70.6% vs. 73.1% for <400 copies/ml and 65.3% vs. 69.3% at <50 copies/ml in the full analysis set (FAS) study population (n= 360, maraviroc/ n= 361, efavirenz), according to a late breaker presentation at the International AIDS Society conference in Sydney, Australia. Increases inmore...
  • 7/19/07 5:26 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending marketing authorization for Celsentri® (maraviroc), the first CCR5 antagonist for use in combination with other antiretroviral agents for treatment-experienced adult patients where only CCR5-tropic virus is detectable. The CHMP’s positivemore...
  • 7/18/07 2:34 pm EDT

    Fabrus LLC to Develop New Antibody Technologies in Search For New Medicines

    NEW YORK--(BUSINESS WIRE)-- Pfizer today announced its first occupant for the company’s Incubator – a new development where scientific entrepreneurs progress their ideas towards innovative treatments for serious diseases. Vaughn Smider MD, PhD, an assistant professor at The Scripps Research Institute, in La Jolla CA, will work to develop a unique technology to identify antibodies that might lead to new therapies. He willmore...
  • 7/18/07 6:45 am EDT
    • Second Quarter 2007 was Impacted by Loss of Exclusivity for Zoloft and Norvasc, Timing of Expenses and Lipitor Performance in the U.S.; New Products Chantix, Sutent, Lyrica are Performing Extremely Well
    • Company Makes Significant Progress Against Priorities Announced in January 2007, including Creating a Lower, More Flexible Cost Base
    • Company Developing Longer-Range Plans for a Rapidly Changing Healthcare Marketplace
    NEW YORK--(BUSINESS WIRE)--Pfizer: ($ millions, except per-share amounts)           Second Quarter   Year to Date     2007  more...
  • 7/10/07 6:45 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the High Court in Dublin, Ireland has ruled that the basic patent covering atorvastatin - the active ingredient in Lipitor - would be infringed by a competitor product from generics manufacturer Ranbaxy. The decision, which is subject to a possible appeal, prevents Ranbaxy from launching its drug before the basic Lipitor patent (Irish Patent Number 60014) expires in November 2011. “more...
  • 7/9/07 12:44 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) has been notified of an unsolicited “mini-tender offer” by TRC Capital Corporation of Toronto (TRC) for TRC to purchase in cash up to four million shares, or approximately 0.057%, of the outstanding Pfizer common stock, at a price of $25.00 per share. TRC’s offer price of $25.00 per Pfizer share represents a 2.31% discount to the closing price on June 26, 2007, the day before themore...
  • 7/3/07 1:50 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a webcast of a conference call with investment analysts at 12 Noon EDST on Wednesday, July 18. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2007 Performance Report, to be issued that morning. To listen to the webcast and view the Performance Report, visit our web sitemore...
  • 6/30/07 5:00 am EDT

    New Data Reinforce Importance of Irinotecan Regimen in First Line Setting

    BARCELONA--(BUSINESS WIRE)--Data presented for the first time in Europe reinforce the position of irinotecan as a key component of first line therapy in the management of patients with metastatic colorectal cancer (mCRC). Colorectal cancer is the most common cancer in Europe, and the third most common cancer worldwide. Each year, 138,000 Europeans die from the disease. However, colorectal cancer is preventable in most cases and highlymore...
  • 6/28/07 9:18 am EDT
    NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer today declared a 29-cent third-quarter, 2007, dividend on the company's common stock, payable September 5, 2007, to shareholders of record at the close of business on August 10, 2007 Pfizer increased its quarterly dividend to 29 cents in the first quarter of 2007 as part of a series of actions the company is taking to enhance shareholder value. The third-quarter 2007 cashmore...